| Attribute |
Value |
| 52 Week Change |
-0.06777495 |
| Address1 |
Hulsterweg 82 |
| All Time High |
62.756256 |
| All Time Low |
1.877324 |
| Ask |
44.9 |
| Ask Size |
300 |
| Audit Risk |
3 |
| Average Analyst Rating |
2.2 - Buy |
| Average Daily Volume10 Day |
3,834,360 |
| Average Daily Volume3 Month |
2,952,119 |
| Average Volume |
2,952,119 |
| Average Volume10Days |
3,834,360 |
| Beta |
0.62 |
| Bid |
40.84 |
| Bid Size |
1,500 |
| Board Risk |
2 |
| Book Value |
16.261 |
| City |
Venlo |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Compensation Risk |
3 |
| Country |
Netherlands |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
43.11 |
| Current Ratio |
2.849 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,786,665,600 |
| Day High |
43.99 |
| Day Low |
42.99 |
| Debt To Equity |
49.25 |
| Display Name |
Qiagen |
| Dividend Date |
1,783,987,200 |
| Dividend Rate |
0.35 |
| Dividend Yield |
0.8 |
| Earnings Call Timestamp End |
1,786,023,000 |
| Earnings Call Timestamp Start |
1,786,023,000 |
| Earnings Growth |
0.079 |
| Earnings Quarterly Growth |
0.074 |
| Earnings Timestamp |
1,785,960,000 |
| Earnings Timestamp End |
1,793,822,400 |
| Earnings Timestamp Start |
1,793,822,400 |
| Ebitda |
734,185,024 |
| Ebitda Margins |
0.34955 |
| Enterprise To Ebitda |
13.297 |
| Enterprise To Revenue |
4.648 |
| Enterprise Value |
9,762,198,528 |
| Eps Current Year |
2.43378 |
| Eps Forward |
2.60967 |
| Eps Trailing Twelve Months |
1.94 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,783,382,400 |
| Exchange |
NYQ |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
41.1628 |
| Fifty Day Average Change |
1.9472008 |
| Fifty Day Average Change Percent |
0.04730487 |
| Fifty Two Week Change Percent |
-6.7774954 |
| Fifty Two Week High |
57.82 |
| Fifty Two Week High Change |
-14.709999 |
| Fifty Two Week High Change Percent |
-0.25441024 |
| Fifty Two Week Low |
32.53 |
| Fifty Two Week Low Change |
10.580002 |
| Fifty Two Week Low Change Percent |
0.32523832 |
| Fifty Two Week Range |
32.53 - 57.82 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
835,968,600,000 |
| Float Shares |
205,134,198 |
| Forward Eps |
2.60967 |
| Forward P E |
16.519331 |
| Free Cashflow |
372,855,136 |
| Full Exchange Name |
NYSE |
| Full Time Employees |
5,500 |
| Fullday Change |
-0.630001 |
| Fullday Change Percent |
-1.44033 |
| Fullday Price |
43.0455 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Governance Epoch Date |
1,785,542,400 |
| Gross Margins |
0.66385 |
| Gross Profits |
1,394,317,952 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.00481 |
| Held Percent Institutions |
0.80189 |
| Implied Shares Outstanding |
206,495,000 |
| Industry |
Diagnostics & Research |
| Industry Disp |
Diagnostics & Research |
| Industry Key |
diagnostics-research |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,783,382,400 |
| Last Dividend Value |
0.35 |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,485,302,400 |
| Last Split Factor |
962:1000 |
| Long Business Summary |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. |
| Long Name |
Qiagen N.V. |
| Market |
us_market |
| Market Cap |
8,901,999,616 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_33471 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
409,316,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
9,032,091,300 |
| Number Of Analyst Opinions |
14 |
| Open |
43.62 |
| Operating Cashflow |
654,470,016 |
| Operating Margins |
0.26325 |
| Overall Risk |
2 |
| Payout Ratio |
0.17790002 |
| Peg Ratio |
1.1 |
| Phone |
31 77 355 6600 |
| Post Market Change |
-0.0644989 |
| Post Market Change Percent |
-0.1496147 |
| Post Market Price |
43.0455 |
| Post Market Time |
1,787,961,399 |
| Previous Close |
43.74 |
| Price Eps Current Year |
17.713188 |
| Price Hint |
2 |
| Price To Book |
2.6511285 |
| Price To Sales Trailing12 Months |
4.2383146 |
| Profit Margins |
0.19488001 |
| Quick Ratio |
2.051 |
| Quote Source Name |
Delayed Quote |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.2 |
| Region |
US |
| Regular Market Change |
-0.630001 |
| Regular Market Change Percent |
-1.44033 |
| Regular Market Day High |
43.99 |
| Regular Market Day Low |
42.99 |
| Regular Market Day Range |
42.99 - 43.99 |
| Regular Market Open |
43.62 |
| Regular Market Previous Close |
43.74 |
| Regular Market Price |
43.11 |
| Regular Market Time |
1,787,947,202 |
| Regular Market Volume |
1,376,257 |
| Return On Assets |
0.0587 |
| Return On Equity |
0.11928 |
| Revenue Growth |
0.003 |
| Revenue Per Share |
10.164 |
| Sand P52 Week Change |
0.20504117 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Share Holder Rights Risk |
5 |
| Shares Outstanding |
206,495,000 |
| Shares Percent Shares Out |
0.049099997 |
| Shares Short |
10,140,064 |
| Shares Short Previous Month Date |
1,784,073,600 |
| Shares Short Prior Month |
7,929,408 |
| Short Name |
Qiagen N.V. |
| Short Percent Of Float |
0.0556 |
| Short Ratio |
3.86 |
| Source Interval |
15 |
| Symbol |
QGEN |
| Target High Price |
50.0 |
| Target Low Price |
40.0 |
| Target Mean Price |
46.07143 |
| Target Median Price |
46.5 |
| Total Cash |
793,500,032 |
| Total Cash Per Share |
3.843 |
| Total Debt |
1,653,698,944 |
| Total Revenue |
2,100,363,008 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.363 |
| Trailing Annual Dividend Yield |
0.00829904 |
| Trailing Eps |
1.94 |
| Trailing P E |
22.22165 |
| Trailing Peg Ratio |
1.1004 |
| Triggerable |
1 |
| Two Hundred Day Average |
42.7501 |
| Two Hundred Day Average Change |
0.35990143 |
| Two Hundred Day Average Change Percent |
0.008418728 |
| Type Disp |
Equity |
| Volume |
1,376,257 |
| Website |
https://www.qiagen.com |
| Zip |
5,912 PL |